Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Chemotherapy in NSCLC Pancoast Tumor
NCT05684276Phase 2Active, not recruiting
- Sponsor
- Fundación GECP
- Start
- May 2023
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Started May 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05684276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684276.